Antibodies that immunospecifically bind to B lymphocyte stimulator protein

• US 9,187,548 B2
• Filed: 01/23/2012
• Issued: 11/17/2015
• Est. Priority Date: 06/16/2000
• Status: Expired due to Fees

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Ruben, Steven M., Barash, Steven C., Choi, Gil H., Vaughan, Tristan, Hilbert, David
• Primary Examiner(s): DUFFY, PATRICIA ANN
• Application Number:
  US13/356,314
• Publication Number:
  US 20120121606A1
• Time in Patent Office: 1,394 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 14/70575 NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 NGF C07K14/48, TNF C07K14/525
• CPC Class Codes: C07K 16/2875 against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 against NGF C07K16/22, against TNF C07K16/241
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Abstract

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

Claims

1. An isolated polynucleic acid encoding an antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator protein comprising a first, second and third nucleic acid sequence, where the first nucleic acid sequence encodes a variable heavy chain domain (VH) that is at least 95% identical to the VH domain of the scFv of SEQ ID NO:

327, the second nucleic acid sequence encodes a variable light chain domain (VL) that is at least 95% identical to the VL domain of the scFV of SEQ ID NO;

327 and the third nucleic acid sequence encodes a heterologous amino acid linker, wherein the first and second nucleic acid sequences of the antibody or fragment thereof are joined together by the third nucleic acid sequence.

2. The isolated polynucleic acid of claim 1 wherein the first nucleic acid encodes an amino acid sequence that is identical to the VH domain of the scFv of SEQ ID NO:

327.

3. The isolated polynucleic acid of claim 1 wherein the second nucleic acid encodes an amino acid sequence that is identical to the VL domain of the scFv of SEQ ID NO:

327.

4. The isolated polynucleic acid of claim 1 wherein the first nucleic acid encodes an amino acid sequence that is identical to the VH domain of the scFv of SEQ ID NO:

327 and the second nucleic acid encodes an amino acid sequence that is identical to the VL domain of the scFv of SEQ ID NO;

327.

5. The isolated polynucleic acid of claim 1 wherein the B Lymphocyte Stimulator is selected from the group consisting of:

(a) a protein whose amino add sequence consists of amino acid residues 1-285 of SEQ ID NO;

3228;

(b) a protein whose amino acid sequence consists of amino add residues 134-285 of SEQ ID NO;

3228; and

(c) a trimer of the protein of (b).

6. An isolated cell comprising the isolated polynucleic acid of claim 1.